新辅助化疗对乳腺癌组织病理学及免疫组织化学的影响  

Effect of neoadjuvant chemotherapy on histopathology and immunohistochemistry in breast cancer

作　　者：汪美华[1] 凌扬[2] 周林艳[1] 

机构地区：[1]苏州大学附属常州肿瘤医院病理科,江苏常州213001 [2]苏州大学附属常州肿瘤医院肿瘤科,江苏常州213001

出　　处：《临床与病理杂志》2015年第3期399-401,共3页Journal of Clinical and Pathological Research

摘　　要：目的:探讨新辅助化疗对乳腺癌组织病理学及免疫组织化学的影响。方法:观察术前经粗针吸活检(core needle biopsy,CNB)确诊的80例乳腺癌新辅助化疗后肿瘤标本的组织病理学改变,并分析其手术前后ER、PR、HER2等免疫表型的变化。结果:新辅助化疗对乳腺癌总显效率为67.5%,手术前后肿瘤组织的ER、PR、HER2总阳性表达率差异无显著性(P>0.05),但ER、PR、HER2均出现较高的不符合率,依次为45.0%、37.5%、12.5%。结论:新辅助化疗能有效地作用于肿瘤组织,并能帮助寻找术后有针对性的化疗方案;但对ER、PR、HER2等免疫标记有较大影响,可能会对术后选择内分泌治疗及靶向治疗造成不确定因素。Objective： To study effect ofneoadjuvant chemotherapy on histopathology and immunohistochemistry in Breast cancer. Methods： Totally 80 breast cancer patients pathologically diagnosed by the core needle biopsy （CNB）, received radical operation after neoadjuvant chemotherapy, the morphological changes and immunohistochemical results of ER, PR and HER2 before and after operation were compared. Results： The total effective rate of neoadjuvant chemotherapy on breast cancer is 67.5%, and there was no significant difference of the expression rates of ER, PR and HER2 between pre- and post-operation （P〉0.05） but expressions of ER（45.0%）, PR（37.5%） and HER2 （12.5%） after operation were discrepancy with those before therapy. Conclusion： Neoadjuvant chemotherapy may be effective to breast cancer, but also helpful to select the appropriate chemotherapy regimens. in other hand, it perhaps interfere with endocrine therapy and targeted therapy for its effect on expression of ER, PR and HER2.

关 键 词：乳腺癌 新辅助化疗 组织病理学 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤]